Skip to content

Research on Nutritional Diagnosis and Treatment Technology for Critically Ill Cardiovascular Patients Based on Precise Measurement of Energy Metabolism

Research on Nutritional Diagnosis and Treatment Technology for Critically Ill Cardiovascular Patients Based on Precise Measurement of Energy Metabolism

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500099807
Enrollment
Unknown
Registered
2025-03-28
Start date
2025-01-07
Completion date
Unknown
Last updated
2025-03-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiovascular disease

Interventions

Intervention group:Based on energy metabolism measurement (indirect energy analyzer measurement) obtain the resting metabolic rate (REE) and provide nutritional support.
Control group:Based on the commonly used H-B formula in clinical practice, calculate the basal metabolic rate and develop a nutritional plan to provide nutritional support.

Sponsors

National Cardiovascular Center, Fuwai Hospital, Chinese Academy of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Age >= 18 years old and = 3 points; 5. I have basic understanding, communication, and written expression abilities; 6. Willing to participate in the study and sign an informed consent form.

Exclusion criteria

Exclusion criteria: 1. History of metabolic diseases: including abnormal glucose metabolism: type 1 diabetes; Abnormal lipid metabolism: obesity, anorexia; Abnormal calcium and phosphorus metabolism: hypercalcemia, hypocalcemia, hyperthyroidism, hypothyroidism, hyperparathyroidism, hypoparathyroidism, parathyroid adenoma; Abnormal bone metabolism: osteoporosis, osteomalacia, and bone malnutrition; 2. Taking drugs that affect metabolism or cause weight loss or alter appetite: Modafenib capsules, Bifidobacterium triple active bacteria capsules, Orlistat capsules, Liraglutide injection, phenformin tablets, compound digestive enzyme capsules; 3. Individuals with a life expectancy of <= 6 months for serious illnesses and cancer patients; 4. Pregnant and lactating women; 5. Participated in other clinical trials within 30 days; 6. The researchers believe that the subjects have other important diseases that are not suitable for participation in this study; 7. Refuse to sign the informed consent form.

Design outcomes

Primary

MeasureTime frame
NUTRIC score;

Secondary

MeasureTime frame
NRS2002 score;Hemoglobin concentration;prealbumin;Skeletal muscle content;

Countries

China

Contacts

Public ContactXiang Li

National Cardiovascular Center, Fuwai Hospital, Chinese Academy of Medical Sciences

dawei1966@126.com+86 136 6124 3591

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026